Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Ovarian Cancer|Breast Cancer|Solid Tumor|Prostate Cancer|Endometrial Cancer
Interventions: DRUG: CYH33
Sponsor: Haihe Biopharma Co., Ltd.